SGLT2 Inhibitors, Rapid Titration, IV Iron Get a Boost in New European HF Guideline
(MedPage Today) -- AMSTERDAM -- SGLT2 inhibitor therapy and other innovations in heart failure (HF) treatment were among the highlights of the updated European guidelines presented here at the European Society of Cardiology Congress and published... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 25, 2023 Category: Urology & Nephrology Source Type: news
SGLT2 Inhibitors Curb AF Post-Ablation Recurrences in T2D SGLT2 Inhibitors Curb AF Post-Ablation Recurrences in T2D
Retrospective, observational data from more than 13,000 US patients with type 2 diabetes and atrial fibrillation suggest that SGLT2 inhibitor treatment may cut AF recurrences post-ablation.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 14, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Studies Examine Links Between Diabetes and Eye Disease, Treatment, Adverse Events
(MedPage Today) -- SEATTLE -- Diabetic patients treated with GLP-1 agonists had significantly more progression of existing diabetic eye disease as compared with those treated with SGLT2 inhibitors, a matched cohort study showed.
Treatment with... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - August 1, 2023 Category: Endocrinology Source Type: news
GLP-1 Inhibitors in HFpEF With Obesity: Are We There Yet? GLP-1 Inhibitors in HFpEF With Obesity: Are We There Yet?
Obesity, a driver of inflammation, is prevalent in patients with HFpEF. Ileana Pina asks Ambarish Pandey about GLP-1 inhibitors and SGLT2 inhibitors in HFpEF. Are these drugs anti-inflammatory?theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 27, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Europe Approves Empagliflozin for Chronic Kidney Disease Europe Approves Empagliflozin for Chronic Kidney Disease
The SGLT2 inhibitor empagliflozin (Jardiance) was approved by European regulators for treating adults with chronic kidney disease. The FDA is reviewing a new drug application for this indication.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - July 27, 2023 Category: Internal Medicine Tags: Diabetes & Endocrinology News Alert Source Type: news
The Connection Between Diabetes and Heart Arrhythmias
The human heart beats roughly 3 billion times during the course of an average lifetime. Every single time it beats, blood is drawn into its two upper chambers, held there briefly by a network of valves, and then pumped out forcefully through its two lower chambers. This drawing-and-pumping action ensures that about six liters of freshly oxygenated blood leaves the heart and enters the bloodstream every minute—a volume that can rise to more than 35 liters per minute when someone is exercising.
[time-brightcove not-tgx=”true”]
But none of that can happen unless the heart’s complicated machinery&md...
Source: TIME: Health - July 25, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate Source Type: news
Saxenda Shortage; New ADA Guidance; Cheap Test for Osteoporosis Risk?
(MedPage Today) -- The shortage of weight-loss drugs now extends to liraglutide (Saxenda). (Fierce Pharma)
Compared with DPP-4 inhibitors, SGLT2 inhibitors helped reduce recurrent gout flare-ups and hospitalizations in people with type 2 diabetes... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - July 25, 2023 Category: Endocrinology Source Type: news
SGLT2 Inhibitors Linked With Fewer Gout Flares in Diabetes SGLT2 Inhibitors Linked With Fewer Gout Flares in Diabetes
In 8150 propensity-score matched Canadians with gout and type 2 diabetes, treatment with an SGLT2 inhibitor was linked with a significant 34% relative drop in gout flares compared with DPP-4 inhibitors.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 24, 2023 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Effect of SGLT2i on Bone and Mineral Metabolism in CKD Effect of SGLT2i on Bone and Mineral Metabolism in CKD
SGLT2 inhibitors have shown beneficial effects in the treatment of patients with CKD -- but how do these agents affect bone and mineral metabolism?Current Opinion in Nephrology and Hypertension (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2023 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
Best Practices for SGLT2 Inhibitors in HFpEF Treatment Best Practices for SGLT2 Inhibitors in HFpEF Treatment
Drs Matthew Konerman and Sarah Adie share expert insights on SGLT2 inhibitor use in managing heart failure with preserved ejection fraction.American College of Cardiology & Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 17, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
First SGLT2 Inhibitor Approved for Kids With Type 2 Diabetes
(MedPage Today) -- Two empagliflozin-containing treatments were FDA approved for pediatric type 2 diabetes, the agency announced on Tuesday.
Once-daily empagliflozin (Jardiance) and empagliflozin/metformin hydrochloride (Synjardy) are now indicated... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 21, 2023 Category: American Health Source Type: news
Low Co-Pays Drive Better Adherence to New Diabetes Drugs Low Co-Pays Drive Better Adherence to New Diabetes Drugs
Low co-pays linked with substantially better 12-month adherence to expensive SGLT2 inhibitors and GLP-1 agonists among US patients with type 2 diabetes or heart failure.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - June 20, 2023 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
Jun 16 2023 This Week in Cardiology Jun 16 2023 This Week in Cardiology
AF screening, BNP, a new SGLT2 inhibitor, a sky-is-blue study, and the UK Mini Mitral surgical trial are discussed in this week ' s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 16, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Metformin, SGLT2is Link With Longer T2D Survival Metformin, SGLT2is Link With Longer T2D Survival
Treatment with metformin or an agent from the SGLT2 inhibitor class linked with significantly better survival in people with type 2 diabetes in UK Biobank data.First Look (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - June 12, 2023 Category: Respiratory Medicine Tags: Diabetes & Endocrinology News Source Type: news
New Nonhormonal Hot Flash Recs; Global Plastics Treaty; SGLT2 & Lower Cancer Risk?
(MedPage Today) -- The North American Menopause Society released an updated position statement on the latest nonhormonal hot flash treatment options. (Menopause)
A longitudinal analysis showed that while kids with type 1 diabetes rapidly progressed... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - June 6, 2023 Category: Endocrinology Source Type: news
